{"entity":{"id":"nct07234877","kind":"trial","name":"Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets","aka":[],"tldr":"A phase 2 trial of ivonescimab, carboplatin, pemetrexed, paclitaxel / nab-paclitaxel and other drugs in lung cancer, run by European Organisation for Research and Treatment of Cancer - EORTC, not yet recruiting.","summary":"Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets is a phase 2, randomised interventional study registered as NCT07234877 by European Organisation for Research and Treatment of Cancer - EORTC, with a registry enrolment figure of 158 participants, started 2026-11 and due to reach its primary completion in 2032-01. Interventions recorded: Ivonescimab; Carboplatin; Pemetrexed; Paclitaxel; Paclitaxel-albumin; Stereotactic Radiosurgery (SRS) or Fractionated Stereotactic Radiotherapy (FSRT). Conditions listed: Non Small Cell Lung Cancer. Primary outcome: Intracranial progression-free survival based on local assessment using RANO-BM criteria. Lung eligibility wording from the registry: \"* Patients with pathology proven metastatic NSCLC without an actionable genomic alteration for which there is first line targeted treatment approved by EMA and recommended by the ESMO guidelines\". Sites: Austria, France, Germany, Greece, Italy, Netherlands, Slovenia, Spain. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT07234877","url":"https://clinicaltrials.gov/study/NCT07234877"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["antiangiogenic","bispecific-antibody","checkpoint-inhibitor","cytotoxic-chemotherapy","platinum","sbrt"],"targets":[],"drugs":["ivonescimab","carboplatin","pemetrexed","paclitaxel","nab-paclitaxel"],"companies":["summit-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07234877","phase":"2","setting":"A Randomized Phase II Study Evaluating Upfront SRT to All Brain Metastases Followed by Ivonescimab Plus Chemotherapy Versus Upfront Ivonescimab Plus Chemotherapy in Patients With Asymptomatic Active Brain Metastases From NSCLC","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","enrolled":158,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07234877/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/"},{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"},{"id":"sbrt","kind":"technology","name":"SBRT / SABR (stereotactic radiotherapy)","route":"/technologies/sbrt/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"ivonescimab","kind":"drug","name":"Ivonescimab","route":"/drugs/ivonescimab/"},{"id":"nab-paclitaxel","kind":"drug","name":"Nab-paclitaxel","route":"/drugs/nab-paclitaxel/"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"},{"id":"pemetrexed","kind":"drug","name":"Pemetrexed","route":"/drugs/pemetrexed/"}],"company":[{"id":"summit-therapeutics","kind":"company","name":"Summit Therapeutics","route":"/companies/summit-therapeutics/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}